Abstract
Comparing drug-injecting risk between cities that differ in the legality of sterile syringe distribution for injection drug use provides a natural experiment to assess the efficacy of legalizing sterile syringe distribution as a structural intervention to prevent human immunodeficiency virus (HIV) and other parenterally transmitted infections among injection drug users (IDUs). This study compares the parenteral risk for HIV and hepatitis B (HBV) and C (HCV) infection among IDUs in Newark, NJ, USA, where syringe distribution programs were illegal during the period when data were collected, and New York City (NYC) where they were legal. IDUs were nontreatment recruited, 2004–2006, serotested, and interviewed about syringe sources and injecting risk behaviors (prior 30 days). In multivariate logistic regression, adjusted odds ratios (AOR) and 95% confidence intervals (95% CI) for city differences are estimated controlling for potential city confounders. IDUs in Newark (n = 214) vs. NYC (n = 312) were more likely to test seropositive for HIV (26% vs. 5%; AOR = 3.2; 95% CI = 1.6, 6.1), antibody to the HBV core antigen (70% vs. 27%; AOR = 4.4; 95% CI = 2.8, 6.9), and antibody to HCV (82% vs. 53%; AOR = 3.0; 95% CI = 1.8, 4.9), were less likely to obtain syringes from syringe exchange programs or pharmacies (AOR = 0.004; 95% CI = 0.001, 0.01), and were more likely to obtain syringes from street sellers (AOR = 74.0; 95% CI = 29.9, 183.2), to inject with another IDU’s used syringe (AOR = 2.3; 95% CI = 1.1, 5.0), to reuse syringes (AOR = 2.99; 95% CI = 1.63, 5.50), and to not always inject once only with a new, sterile syringe that had been sealed in a wrapper (AOR = 5.4; 95% CI = 2.9, 10.3). In localities where sterile syringe distribution is illegal, IDUs are more likely to obtain syringes from unsafe sources and to engage in injecting risk behaviors. Legalizing and rapidly implementing sterile syringe distribution programs are critical for reducing parenterally transmitted HIV, HBV, and HCV among IDUs.
Similar content being viewed by others
References
Des Jarlais DC, Marmor M, Paone D, et al. HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet. 1996;348(9033):987–991.
Bluthenthal RN, Kral AH, Gee L, Erringer EA, Edlin BR. The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS. 2000;14(5):605–611.
Centers for Disease Control and Prevention. Update: syringe exchange programs—United States, 2002. Morb Mort Wkly Rep. 2005;54(27):673–676.
Bailey SL, Huo D, Garfein RS, Ouellet LJ. The use of needle exchange by young injection drug users. J Acquir Immune Defic Syndr. 2003;34(1):67–70.
Hagan H, Des Jarlais DC, Friedman SR, Purchase D, Alter MJ. Reduced risk of Hepatitis B and Hepatitis C among injecting drug users participating in the Tacoma Syringe-Exchange Program. Am J Public Health. 1995;85(11):1531–1537.
Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol. 1999;149(3):203–213.
Normand J, Vlahov D, Moses L. Preventing HIV Transmission: The Role of Sterile Needles and Bleach. Washington, DC: National Academy; 1995.
Gibson DR, Flynn NM, Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS. 2001;15(11):1329–1341.
Ksobiech K. A meta-analysis of needle sharing, lending, and borrowing behaviors of needle exchange program attenders. AIDS Educ Prev. 2003;15(3):257–268.
Huo D, Ouellet LJ. Needle exchange and injection-related risk behaviors in Chicago: a longitudinal study. J Acquir Immune Defic Syndr. 2007;45(1):108–114.
Burris S, Vernick JS, Ditzler A, Strathdee S. The legality of selling or giving syringes to injection drug users. J Am Pharm Assoc (Wash). 2002;42(6 Suppl 2):S13–S18.
Bluthenthal RN, Malik MR, Grau LE, Singer M, Marshall P, Heimer R. Sterile syringe access conditions and variations in HIV risk among drug injectors in three cities. Addiction. 2004;99(9):1136–1146.
Taussig JA, Weinstein B, Burris S, Jones TS. Syringe laws and pharmacy regulations are structural constraints on HIV prevention in the US. AIDS. 2000;14(Suppl 1):S47–S51.
Rockwell R, Des Jarlais DC, Friedman SR, Perlis TE, Paone D. Geographic proximity, policy and utilization of syringe exchange programmes. AIDS Care. 1999;11(4):437–442.
Bluthenthal RN, Kral AH, Lorvick J, Watters JK. Impact of law enforcement on syringe exchange programs: a look at Oakland and San Francisco. Med Anthropol. 1997;18(1):61–83.
Davis CS, Burris S, Kraut-Becher J, Lynch KG, Metzger D. Effects of an intensive street-level police intervention on syringe exchange program use in Philadelphia, PA. Am J Public Health. 2005;95(2):233–236.
New York State Department of Health. Expanded Syringe Access Demonstration Program (ESAP): Overview of the Law and Regulations. Accessed on: January 31, 2008. Available at: http://www.health.state.ny.us/diseases/aids/harm_reduction/needles_syringes/esap/overview.htm.
Center for Urban Epidemiologic Studies, New York Academy of Medicine, Beth Israel Medical Center, and National Development and Research Institutes. New York State Expanded Syringe Access Demonstration Program Evaluation. New York: New York Academy of Medicine; 2003.
Fuller CM, Ahern J, Vadnai L, et al. Impact of increased syringe access: preliminary findings on injection drug user syringe source, disposal, and pharmacy sales in Harlem, New York. J Am Pharm Assoc (Wash). 2002;42(6 Suppl 2):S77–S82.
Rhodes T, Stimson GV, Crofts N, Ball A, Dehne K, Khodakevich L. Drug injecting, rapid HIV spread, and the ‘risk environment’: implications for assessment and response. AIDS. 1999;13(Suppl A):259–269.
Des Jarlais DC. Structural interventions to reduce HIV transmission among injecting drug users. AIDS. 2000;14(Suppl 1):S41–S46.
Bruneau J, Lamothe F, Franco E, et al. High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study. Am J Epidemiol. 1997;146(12):994–1002.
Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997;11(8):F59–F65.
Schechter MT, Strathdee SA, Cornelisse PG, et al. Do needle exchange programmes increase the spread of HIV among injection drug users?: an investigation of the Vancouver outbreak. AIDS. 1999;13(6):F45–F51.
Wood E, Lloyd-Smith E, Li K, et al. Frequent needle exchange use and HIV incidence in Vancouver, Canada. Am J Med. 2007;120(2):172–179.
Archibald CP, Ofner M, Strathdee SA, et al. Factors associated with frequent needle exchange program attendance in injection drug users in Vancouver, Canada. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17(2):160–166.
Hagan H, McGough JP, Thiede H, Hopkins SG, Weiss NS, Alexander ER. Volunteer bias in nonrandomized evaluations of the efficacy of needle-exchange programs. J Urban Health. 2000;77(1):103–112.
Fisher DG, Reynolds GL, Harbke CR. Selection effect of needle exchange in Anchorage, Alaska. J Urban Health. 2002;79(1):128–135.
Valente TW, Foreman RK, Junge B, Vlahov D. Satellite exchange in the Baltimore Needle Exchange Program. Public Health Rep. 1998;113(Suppl 1):90–96.
National Institutes of Health. Interventions to prevent HIV risk behaviors. NIH Consensus Statement. Feb 11–13. 1997;15(2):1–41.
Shalala D. Needle Exchange Programs in America: Review of Published Studies and Ongoing Research. Report to the Committee on Appropriations for the Departments of Labor, Health and Human Services, Education and Related Agencies. February 18, 1997.
Centers for Disease Control and Prevention. Incorporating HIV prevention into the medical care of persons living with HIV: recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2003;52(RR-12):1–24.
US Census Bureau. Population by Race and Hispanic or Latino Origin, for All Ages and for 18 Years and Over, for the United States: 2000. Accessed on: January 31, 2008. Available at: http://www.census.gov/main/www/cen2000.html.
Sifaneck SJ, Neaigus A. The ethnographic accessing, sampling and screening of hidden populations: heroin sniffers in New York City. Addict Res Theory. 2001;9(6):519–543.
Watters J, Biernacki P. Targeted sampling: options for the study of hidden populations. Soc Probl. 1989;6(4):416–430.
Heckathorn DD. Respondent-driven sampling: a new approach to the study of hidden populations. Soc Probl. 1997;44(2):174–199.
Friedman SR, Chapman TF, Perlis TE, et al. Similarities and differences by race/ethnicity in changes of HIV seroprevalence and related behaviors among drug injectors in New York City, 1991–1996. J Acquir Immune Defic Syndr. 1999;22:83–91.
Centers for Disease Control and Prevention. HIV/AIDS among African Americans. CDC HIV/AIDS Fact Sheet. Accessed on: January 31, 2008. Available at: http://www.cdc.gov/hiv/topics/aa/resources/factsheets/aa.htm.
Friedman SR, Des Jarlais DC, Neaigus A, et al. AIDS and the new drug injector. Nature. 1989;339(6223):333–334.
Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health. 1996;86(5):642–654.
Latkin CA, Forman VL. Patterns of needle acquisition and sociobehavioral correlates of needle exchange program attendance in Baltimore, Maryland, U.S.A. J Acquir Immune Defic Syndr. 2001;27(4):398–404.
Latkin CA, Hua W, Davey MA. Exploring the role of needle selling in a drug-using community in Baltimore, Maryland. J Acquir Immune Defic Syndr. 2005;38(1):57–60.
Bluthenthal RN, Anderson R, Flynn NM, Kral AH. Higher syringe coverage is associated with lower odds of HIV risk and does not increase unsafe syringe disposal among syringe exchange program clients. Drug Alcohol Depend. 2007;89(2–3):214–222.
Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health. 2001;91(1):42–46.
Neaigus A, Gyarmathy VA, Miller M, et al. Injecting and sexual risk correlates of HBV and HCV seroprevalence among new drug injectors. Drug Alcohol Depend. 2007;89(2–3):234–243.
Neaigus A, Gyarmathy VA, Zhao M, Miller M, Friedman SR, Des Jarlais DC. Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users. J Infect Dis. 2007;195(7):1052–1061.
Morgenstern H. Ecologic studies. In: Rothman KJ, Greenland S, eds. Modern Epidemiology. Philadelphia: Lippincott Williams & Wilkins; 1998:459–480.
Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006;41(6–7):777–813.
Watters JK, Estilo MJ, Clark GL, Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA. 1994;271(2):115–120.
Vlahov D, Junge B. The role of needle exchange programs in HIV prevention. Public Health Rep. 1998;113(Suppl 1):75–80.
van Ameijden EJC, Coutinho RA. Large decline in injecting drug use in Amsterdam, 1986–1998: explanatory mechanisms and determinants of injecting transitions. J Epidemiol Community Health. 2001;55:356–363.
Neaigus A, Gyarmathy VA, Miller M, Frajzyngier VM, Friedman SR, Des Jarlais DC. Transitions to injecting drug use among non-injecting heroin users: social network influence and individual susceptibility. J Acquir Immune Defic Syndr. 2006;41(4):493–503.
Hurley SF, Jolley DJ, Kaldor JM. Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet. 1997;349(9068):1797–1800.
New Jersey Department of Health and Senior Services, Division of HIV/AIDS Services. Prevalence Rate of Top Ten Cities With HIV/AIDS Reported As Of June 30, 2006. Accessed on: January 31, 2008. Available at: http://www.state.nj.us/health/aids/repa/cities.shtml.
New Jersey Department of Health and Senior Services, Division of HIV/AIDS Services, Epidemiologic Services Unit. Persons reported with HIV/AIDS in City of Newark, 7/1/2005–6/30/2006. Report from Dr. Helene Cross, Ph.D., Director of the Epidemiologic Services Unit. July 6 2007.
New York City Department of Health and Mental Hygiene. New York City HIV/AIDS Annual Surveillance Statistics 2005. New York, NY: Department of Health and Mental Hygiene; 2006.
Acknowledgments
The study was funded by the US National Institute on Drug Abuse, grant R01 DA014515 “HIV Risk and Neighborhood Networks of IDUs” (Principal Investigator: Alan Neaigus). We would like to thank Vera Frajzyngier for assisting in directing the data collection and other members of our research staff at the National Development and Research Institutes who worked on the study. The North Jersey Community Research Initiative (NJCRI) in Newark, NJ, USA, and their outreach staff provided major support for data collection in Newark, and Corey Rosmarin and the phlebotomy staff at NJCRI provided assistance in the collection of blood specimens for the Newark participants. This research would not have been possible without the consent of the drug users who agreed to participate in this study.
Author information
Authors and Affiliations
Corresponding author
Additional information
Neaigus, Zhao, Gyarmathy, and Cisek are with the Institute for International Research on Youth at Risk, National Development and Research Institutes, New York, NY, USA; Neaigus is with the Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA; Gyarmathy is with the Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA; Friedman is with the Institute for AIDS Research, National Development and Research Institutes, New York, NY, USA; Friedman is with the Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA; Baxter is with the North Jersey Community Research Initiative, Newark, NJ, USA.
Rights and permissions
About this article
Cite this article
Neaigus, A., Zhao, M., Gyarmathy, V.A. et al. Greater Drug Injecting Risk for HIV, HBV, and HCV Infection in a City Where Syringe Exchange and Pharmacy Syringe Distribution are Illegal. J Urban Health 85, 309–322 (2008). https://doi.org/10.1007/s11524-008-9271-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11524-008-9271-1